Imunon, Inc. · NASDAQ:IMNN

Imunon — Investor Day (September 2026)

59 slides from Imunon's investor day presentation, Sep 23, 2026

  1. Slide 1: IMUNON’s 2026 Investor Conference and R&D Day

    IMUNON’s 2026 Investor Conference and R&D Day September 23, 2026 10:00 AM-12:00 PM EDT Sofitel, New York City © 2022 IMUNON, Inc. PAGE 1

  2. Slide 2: Agenda

    Agenda Welcome - Redefining Frontline Care: Unlocking the Stacy Lindborg, PhD President and CEO, Imunon, Inc. Potential of a First-in-Class IL-12 Immunotherapy in Ovarian Cancer Resurrecting IL-12: Overcoming Historical Barriers Douglas Faller, MD, PhD Chief Medical Officer, Imunon, Inc with Targete

  3. Slide 3: Leave with three things.

    REDEFI N I N G FRON T LI N E C A RE · UN LOC KI N G FI RST -I N -CLASS I L -1 2 I MMUN OT HERAPY I N OVA RI A N C A N C ER Leave with three things. A frontline ovarian cancer program now in Phase 3. Built on randomized Phase 2 OS — and on a cytokine the field abandoned. THE PROBLEM THAT HAS NOT MOVE

  4. Slide 4: Resurrecting IL-12: Overcoming Historical Barriers with Targeted TheraPlas Delivery of IMNN-001

    Resurrecting IL-12: Overcoming Historical Barriers with Targeted TheraPlas Delivery of IMNN-001 Douglas V. Faller, MD, PhD Chief Medical Officer

  5. Slide 5: IMNN-001: The First and Only Treatment to Demonstrate an Impact on Overall Survival

    5 IMNN-001: The First and Only Treatment to Demonstrate an Impact on Overall Survival in Newly Diagnosed Advanced Ovarian Cancer Potential to Transform the Frontline Standard of Care for Ovarian Cancer Patients An immunotherapy that harnesses A mechanism of action that the patient’s own immune activ

  6. Slide 6: IL-12 and its Effector IFN-γ: Critical Drivers of Antitumor Immunity

    IL-12 and its Effector IFN-γ: Critical Drivers of Antitumor Immunity Harnessing Both Innate and Acquired Immunity Innate Immunity Acquired Immunity • Monocytes • T lymphocytes • Macrophages • B lymphocytes • Dendritic Cells • Neutrophils • NK cells Image adapted from: Giorgio Trinchieri March 2003 N

  7. Slide 7: IFN-γ Effects in Cancer are Multifactorial and Powerful

    7 IFN-γ Effects in Cancer are Multifactorial and Powerful Not Just Immune-Related but Also Affecting Pathways Regulating Cancer Progression, Angiogenesis and Apoptosis Tumor dormancy ↑IP-10 Image adapted from: Jorgovanovic D et al., . Biomark Res. 2020 © 2022 IMUNON, Inc. PAGE 7

  8. Slide 8: IL-12 in Cancer Immunotherapy is Biologically Powerful

    IL-12 in Cancer Immunotherapy is Biologically Powerful The Challenge has Been to Harness it Locally 38 systemic trials; no OVATION-1: IMNN-001 + IL-12 discovered; potent meaningful benefit (DLTs chemo with encouraging antitumor activity in mice blocked dose escalation) clinical responses 1989–93 199

  9. Slide 9: IMNN-001 Superior Positioning Relative to Other IL-12 Delivery Strategies

    IMNN-001 Superior Positioning Relative to Other IL-12 Delivery Strategies Shared Goal: Maximize Tumor-Local IL-12 While Limiting Systemic Exposure Evolving IL-12 Platforms Key Translational Challenges IMNN-001 Positioning ● Intratumoral mRNA/LNP systems drive ● Systemic recombinant IL-12: poor ● Reg

  10. Slide 10: IMNN-001: Local IL-12 Production in the Tumor Microenvironment

    IMNN-001: Local IL-12 Production in the Tumor Microenvironment Durable Peritoneal Expression Without Bolus-Like Systemic IL-12 Spikes IMNN-001 Intraperitoneal IMNN-001 produces durable, local IL-12 in the peritoneum. Avoids the supraphysiologic IL-12 spikes of bolus IV rIL-12, limiting systemic expo

  11. Slide 11: TheraPlas: Local, Durable Protein for Repeated Administration

    TheraPlasTM: Local, Durable Protein for Repeated Administration TheraPlas combines a therapeutic gene plasmid and proprietary delivery system into nanoparticles to achieve durable local production of a therapeutic protein after in vivo administration at the disease site Gene Expression Therapeutic P

  12. Slide 12: IP IMNN-001 in Advanced Epithelial Ovarian Cancer: Localized Delivery for Diffuse Disease

    IP IMNN-001 in Advanced Epithelial Ovarian Cancer: Localized Delivery for Diffuse Disease Designed to Convert a Cold Peritoneal TME to a Hot Antitumor TME IFN- activates anti-tumor IFN- inhibits immune TME response suppressive TME © 2022 IMUNON, Inc. PAGE 12

  13. Slide 13: IMNN-001: Biomarker Data Consistent with TME Remodeling in Ph1 and Ph2 Studies

    IMNN-001: Biomarker Data Consistent with TME Remodeling in Ph1 and Ph2 Studies Immune Biomarkers Measured in Clinical Samples Confirm IMNN-001 Mechanism of Action OVATION-2 OVATION-1 OVATION-2 Marked Dose-Dependent Increase in Anti-Cancer Cytokine Levels at the tumor site IMNN-001 creates a “hot” an

  14. Slide 14: OVATION-2 Safety: Demonstrating the Successful Overcoming of Historical IL-12 Barriers

    OVATION-2 Safety: Demonstrating the Successful Overcoming of Historical IL-12 Barriers IMNN-001 Allows Safe and Tolerable Repeated Delivery of Tumor-Localized IL-12 (Safety Population) Control arm Experimental arm Subjects with at Least One, n (N/ACT) (IMNN-001 + N/ACT) (%) n=58 N=59 TEAEs 56 (96.6)

  15. Slide 15: IMNN-001 Consistent Safety Profile: OVATION-2, OVATION-3 and MRD Trial Safety

    IMNN-001 Consistent Safety Profile: OVATION-2, OVATION-3 and MRD Trial Safety IMNN-001 Continues to Allow Safe and Tolerable Repeated Delivery of Tumor-Localized IL-12 ▪ No cytokine release syndrome ▪ No serious systemic toxicity ▪ No immune-related adverse events ▪ Consistent safety profile observe

  16. Slide 16: IMNN-001: Defining the Modern Era of IL-12 in Cancer Immunotherapy

    IMNN-001: Defining the Modern Era of IL-12 in Cancer Immunotherapy Reliable Flexible expression and scalable of IL-12 manufacturing Induction of Direct immune access to response the TME Limited Stability of systemic drug product exposure at 4°C IMNN-001 potential in other cancers · gastric, pancreat

  17. Slide 17: IMNN-001 Current and Potential Future Indications

    IMNN-001 Current and Potential Future Indications Platform Capable of a Pipeline of DNA-Based Transformative Medicines Platform Delivery Program Indication(s) Discovery IND Phase 1 Phase 2 Phase 3 enabling Newly Diagnosed Adv. IL-12 (OVATION 3) IMNN-001 enrolling Ovarian Cancer IL-12 in combination

  18. Slide 18: Thank you

    Thank you © 2024 IMUNON, Inc. PAGE 18

  19. Slide 19: Phase II Randomized Translation Study of Clinical and Biological Changes Induced by IMNN-001 (MRD)

    Phase II Randomized Translation Study of Clinical and Biological Changes Induced by IMNN-001 (MRD) Phase in Advanced Stage High Grade Serous Ovarian Cancer Amir Jazaeri, MD Professor and David Gershenson Chair in Ovarian Cancer Research Vice Chair for Clinical Research Director of Gynecologic Cancer

  20. Slide 20: MRD Study Rationale

    MRD* Study Rationale • Frontline therapy offers the best opportunity to achieve cure for ovarian cancer. • IL-12 boost adaptative immunity in “cold” tumors. Systemic IL-12 is poorly tolerated; intraperitoneal delivery has a favorable safety profile. • Combining IL-12 with chemotherapy has been shown

  21. Slide 21: MRD Study Design

    Screening Frontline Therapy Maintenance Therapy NACT+BEV+IMNN-001 ACT+BEV+IMNN-001 HRD: BEV+Olaparib for 4 cycles for 3 cycles HRP: BEV+IMNN-001 Interval Cytoreductive Surgery Diagnostic Laparoscopy MRD Detection by SLL Experimental Suspected Arm Stage III/IV OVCA patients IP Port recommended R Plac

  22. Slide 22: Clinical Data Updates

    Clinical Data Updates R A D I C A L C O L L A B O R AT I O N 22

  23. Slide 23: Clinical and Demographic Data for ITT Cohort

    Clinical and Demographic Data for ITT Cohort Overall Control Exp Characteristic p-value N = 261 N = 121 N = 141 Age at randomization, years 66.5 (62.0, 72.0) 68.5 (61.5, 72.0) 65.0 (62.0, 71.0) 0.5 Race 0.2 Asian 1 (3.8%) 1 (8.3%) 0 (0%) Other 1 (3.8%) 1 (8.3%) 0 (0%) White 24 (92%) 10 (83%) 14 (100

  24. Slide 24: Treatment Course and SLL Outcome for ITT Cohort

    Treatment Course and SLL Outcome for ITT Cohort MRD positive rate in control arm (lower is better): 66.7% (6/9) MRD positive rate in experimental arm: 44.4% (4/9) ctDNA clearance rate in control arm (higher is better): 62.5% (5/8*), ctDNA clearance rate in experimental arm: 87.5% (7/8*) *1 participa

  25. Slide 25: Clinical Characteristics (Evaluable Patients)

    Clinical Characteristics (Evaluable Patients) Overall Control Experimental Characteristic p-value N = 181 N = 91 N = 91 Time to ICS, months 3.5 (3.1, 4.4) 3.3 (3.1, 4.1) 3.7 (3.2, 4.4) 0.14 CRS 0.5 1 2 (12%) 2 (25%) 0 (0%) 2 10 (59%) 4 (50%) 6 (67%) 3 5 (29%) 2 (25%) 3 (33%) Not yet available 1 1 0

  26. Slide 26: Recurrence-Free Survival: Median Twice as Long in the Experimental Arm

    Recurrence-Free Survival: Median Twice as Long in the Experimental Arm ITT population R A D I C A L C O L L A B O R AT I O N 26

  27. Slide 27: Translational Data Updates

    Translational Data Updates R A D I C A L C O L L A B O R AT I O N 27

  28. Slide 28: Imunon Translational Study Design and Sample Collection

    Imunon Translational Study Design and Sample Collection S = sample P = patient R A D I C A L C O L L A B O R AT I O N 28

  29. Slide 29: Integrating all Samples (Visium HD Data)

    Integrating all Samples (Visium HD Data) R A D I C A L C O L L A B O R AT I O N 29

  30. Slide 30: Integrating all Samples (Visium HD Data)

    Integrating all Samples (Visium HD Data) Fib_OGN Fib_STAR R A D I C A L C O L L A B O R AT I O N 30

  31. Slide 31: Proportion Among TME Cells Over Time (Visium HD Data)

    Proportion Among TME Cells Over Time (Visium HD Data) R A D I C A L C O L L A B O R AT I O N 31

  32. Slide 32: IL-12 expression in macrophages IL-12 expression in iCAF

    IL-12 expression in macrophages IL-12 expression in iCAF IL-12A IL-12A IL-12B IL-12B R A D I C A L C O L L A B O R AT I O N 32

  33. Slide 33: Spatial Map of Samples (Interval Surgery - Exp Arm)

    Spatial Map of Samples (Interval Surgery - Exp Arm) R A D I C A L C O L L A B O R AT I O N 33

  34. Slide 34: IL-12A/B Density

    IL-12A/B Density R A D I C A L C O L L A B O R AT I O N 34

  35. Slide 35: IL-12-Positive Spatial Field Across Control, Experimental Arm Samples

    IL-12-Positive Spatial Field Across Control, Experimental Arm Samples p.adj = 0.0004 p.adj = 0.0016 Clinical Group R A D I C A L C O L L A B O R AT I O N 35

  36. Slide 36: Spatial and Phenotypic Features of IL-12-Positive Spatial Field

    Spatial and Phenotypic Features of IL-12-Positive Spatial Field Fib_STAR R A D I C A L C O L L A B O R AT I O N 36

  37. Slide 37: Longitudinal Changes of TCR Clones (scTCR-seq Data)

    Longitudinal Changes of TCR Clones (scTCR-seq Data) Top 15 clone FC (baseline -> peak) Log2FC (baseline -> peak) Exp Exp Ctl Ctl MRD- MRD+ MRD- MRD+ R A D I C A L C O L L A B O R AT I O N 37

  38. Slide 38: Summary

    Summary • While preliminary, our data demonstrate lower MRD positive rates and higher CRS, lower NED positive rates, and PFS in the chemo + IMNN-001 arm • IMNN-001 treatment may drive the expansion of macrophages, with a concurrent reduction of myeloid cancer associated fibroblast (myCAF) • Macropha

  39. Slide 39: Future Directions

    Future Directions • Complete enrollment on the MRD Study and first abstract in 2027 • Integration of transcriptomics (RNA) with CODEX (protein) data to better understand the IL-12+ spatial field • Integration with genomic data to understand tumor clonal evolution and the TME of tumor clones • Analys

  40. Slide 40: Advancing Frontline Efficacy: Translating OVATION 2 Overall Survival Signals into Pivotal Phase 3 OVATION 3

    Advancing Frontline Efficacy: Translating OVATION 2 Overall Survival Signals into Pivotal Phase 3 OVATION 3 Premal H. Thaker, MD David & Lynn Mutch Distinguished Professor of Obstetrics & Gyn, Chief of Gynecologic Oncology, Director of Gynecologic Oncology Clinical Research, Professor in Gynecologic

  41. Slide 41: Ovarian Cancer: One of the Deadliest Gynecologic Malignancies

    Ovarian Cancer: One of the Deadliest Gynecologic Malignancies Despite decades of research, current treatments remain insufficient to change that. No improvement in survival from front-line therapies for more than 25 years. 12,450 51.6% ~80% U.S. deaths estimated in 2026 5-year relative survival rate

  42. Slide 42: Ovarian Cancer Current State: Difficult to Detect. Difficult to Control.

    Ovarian Cancer Current State: Difficult to Detect. Difficult to Control. Treatment can be physically demanding (major abdominal surgery and chemo); cancer can Disease Burden Recurrence Burden become resistant to chemo Treatment Ovarian cancer is often discovered late. Recurrence is common. Desperate

  43. Slide 43: A Frontline Blueprint: Immunotherapy Inside the Standard Perioperative Path

    A Frontline Blueprint: Immunotherapy Inside the Standard Perioperative Path What Phase 2, OVATION 2 and MRD, has Taught Us • Localized IL-12, Systemic Safety OVATION-2 Study Schema • Demonstrated change in the tumor microenvironment SoC N/ACT alone (control arm) • Early treatment regimen (with neoad

  44. Slide 44: OVATION 2 Data Show Continued IMNN-001 OS Improvement

    OVATION 2 Data Show Continued IMNN-001 OS Improvement ITT, all-comers population: July 2024 Δ medians 11.1 months → FINAL Analysis: Dec 2025 Δ medians 14.7 months PARPi maintenance treated population: July 2024 Δ medians NE→ FINAL Analysis: Dec 2025 Δ medians 24.2 months From clinically meaningful t

  45. Slide 45: OVATION-2 Biomarker Research Confirms Local Immune Activation at the Tumor Site

    OVATION-2 Biomarker Research Confirms Local Immune Activation at the Tumor Site IMNN-001 creates a “hot” anti-tumor microenvironment in EOC CD8+ T-cells Anti-tumoral HOT Myeloid dendritic cells cells M1 macrophages Immunosupp- Treg-cells ressive cells COLD MDSC - M2 macrophages Anwer et al.,SITC, 20

  46. Slide 46: OVATION-2: A Consistency of Evidence

    OVATION-2: A Consistency of Evidence All Primary and Secondary Endpoints, and Safety Profile, Favor IMNN-001 Given the positive effect across a variety of subgroups and endpoints And the biologic effects of the mechanism of action A positive safety profile (no cytokine release, systemic toxicity or

  47. Slide 47: OVATION Data: Why is This Important?

    OVATION 2 Data: Why is This Important? What the Doctor Sees and What the Patient Feels Physician Perspective Patient Perspective • Clinical win for the sickest patients: those • Hope after decades of little progress: starting NACT, not a selected PARPi- more than a year of additional life — time mai

  48. Slide 48: Case Study

    Case Study 5 P|SHTEMAN

  49. Slide 49: IMNN-001 in Combination with N/ACT Demonstrated a Deep and Durable Response in a Patient

    IMNN-001 in Combination with N/ACT Demonstrated a Deep and Durable Response in a Patient with Stage IV, High Grade Carcinoma, BRCA Mutant and HRD • Patient: 45-year-old, female • Diagnosis: Stage IV, high grade serous carcinoma, BRCA/HRD • Tumor present in ovary, peritoneum, omentum, ascites and in

  50. Slide 50: OVATION-3 Pivotal Phase 3 Study

    OVATION-3 Pivotal Phase 3 Study A Randomized Phase III Trial Evaluating the Safety and Efficacy of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Standard Neoadjuvant and Adjuvant Chemotherapy in Newly Diagnosed Patients with

  51. Slide 51: OVATION-3: Purposeful Protocol Design and Rigorous Methodology

    OVATION-3: Purposeful Protocol Design and Rigorous Methodology Leveraging OVATION-2 Signals and Structure Frontline Therapy Maintenance Therapy Laparoscopy NACT (3 cycles) + ACT (3 cycles) + PARPi treatment: HRD Interval Debulking Surgery IMNN-001 (weekly) IMNN-001 (weekly) participants only N=500 S

  52. Slide 52: OVATION-3: Study Momentum Motivated by Phase 2 Results

    OVATION-3: Study Momentum Motivated by Phase 2 Results Strong Progress Demonstrates Confidence • Advanced from protocol submission to site activation in approximately 6 months • Protocol approval to first patient randomized in approximately 2 months, a third of the time of the external industry benc

  53. Slide 53: If Replicated in Phase 3, IMNN-001 Will Be Included in Global Standard of Care

    If Replicated in Phase 3, IMNN-001 Will Be Included in Global Standard of Care IMNN-001 results provide great hope due to: • Mechanism of Action with IL-12, and IFN- downstream effector cytokine, well documented to exert profound anti-tumor activity • Delivery to the tumor microenvironment induces

  54. Slide 54: IMNN-001: From Fighting Ovarian Cancer to Changing its Trajectory

    IMNN-001: From Fighting Ovarian Cancer to Changing its Trajectory Targeting ovarian Delay relapse, Ultimately transform Extend survival ovarian cancer cancer where it starts treatment outlooks Change the trajectory Frontline Immunity Women diagnosed before recurrence Localized tomorrow should not de

  55. Slide 55: Thank you

    Thank you fF) SITEMAN CANCER CENTER

  56. Slide 56: Beyond the Data: Clinical Experience with IMNN-001

    IMUNON R&D DAY 2026 VIDEO INTERVIEW Beyond the Data Clinical Experience with IMNN-001 A Conversation with an OVATION 1 Study Participant WITH William Bradley, MD Professor and Vice Chair for Clinical Research Division of Gynecologic Oncology Medical College of Wisconsin PLAY VIDEO INTERVIEW William

  57. Slide 57: Confirm the Signal.

    B U I L DI N G T H E F U T U R E · S T R A T E G I C M I L E S T O N E S , C A T A L Y S T S , A N D T H E I N V E S T M E N T H O R I Z O N Confirm the Signal. First-in-class locally delivered IL-12. A randomized overall-survival signal the field has not seen. A Phase 3 already underway. OVATION 2

  58. Slide 58: Questions & Discussion

    IMUNON 2026 R&D DAY NASDAQ: IMNN LIVE DISCUSSION Questions & Discussion We welcome questions from those joining us in New York and via webcast. I N T HE RO O M O N T HE W E BC A ST A F T E R T HE E VE N T Please raise your hand. Submit questions through the Follow-up inquiries: A microphone will be

  59. Slide 59: IMUNON’s 2026 Investor Conference and R&D Day

    IMUNON’s 2026 Investor Conference and R&D Day September 23, 2026 Sofitel, New York City © 2022 IMUNON, Inc. PAGE 59

Imunon — Investor Day (September 2026) on 6ix